Marty Tenenbaum, PhD Founder of Cancer Commons

  • October 8, 2020  

    Pediatric Cancer: The “Day One Talk” Bookmark

    Marty Tenenbaum, PhD

    Article from the Journal of Clinical Oncology, curated by Cancer Commons founder Marty Tenenbaum, PhD.

    This piece discusses a “method of delivering bad news to parents of children with cancer in hopes that our approach may be helpful to others and may spur discussion.”

    .

  • July 16, 2018  

    Proposed FDA “Conditional Approval”- More Details

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published May 10, 2017 Q: Your April 5, 2017 blog post that proposed a new “Conditional” category for FDA drug approval elicited a number of positive and negative responses. Please explain the proposal in more detail… Read more »

  • July 2, 2018  

    A Proposed New FDA Drug Approval Pathway: “Conditional”

    With: Marty Tenenbaum, PhDAl Musella, DPM

    A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY, and Marty Tenenbaum, PhD, Founder and Chair, Cancer Commons, Los Altos, CA Originally published April 5, 2017 Q: The delay time from discovery/observation, through validation to approval and distribution/use of new cancer treatments remains excessive. With promising experimental treatments, advanced computer technology and biostatistics, creative alternatives… Read more »